Pharma’s Almanac’s Q2 2024 roundtable ‘What are the current investment trends in the pharmaceutical industry and how are they influencing the sector’s direction?’ features a response from Nigel Theobald, CEO, N4 Pharma.

Contributing to the discussion, Nigel highlights the need for investment into new non-lipid delivery systems like Nuvec® in the pre-clinical phase.

“It is difficult for new technologies to raise funds, particularly in the UK. Investors can help bring new them further along the pipeline, so that more of them are available for M&A and commercialization.”

Read the full roundtable discussion here: